Xinhua
25 Nov 2021, 21:35 GMT+10
Study showed that the vaccine was 90.7 percent effective at preventing symptomatic COVID-19. The EMA concluded that the benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19.
THE HAGUE, Nov. 25 (Xinhua) -- The European Medicines Agency (EMA) on Thursday recommended the use of COVID-19 vaccine Comirnaty developed by BioNTech and Pfizer for children aged 5 to 11.
The vaccine is already approved for use in adults and children aged 12 and above.
In children from 5 to 11 years of age, the dose of Comirnaty will be lower than that used in people aged 12 and above, the drug agency of the European Union (EU) said in a statement, adding that as in the older age group, it is given as two injections in the muscles of the upper arm, three weeks apart.
A main study in children aged 5 to 11 showed that the immune response to Comirnaty given at a lower dose in this age group was comparable to that seen with the higher dose in 16- to 25-year-olds, as measured by the level of antibodies against SARS-CoV-2, the EMA said.
The efficacy of Comirnaty was calculated in almost 2,000 children from 5 to 11 years of age who had no sign of previous infection, it said.
Study showed that the vaccine was 90.7 percent effective at preventing symptomatic COVID-19. The most common side effects in children aged 5 to 11 are similar to those in people aged 12 and above.
They include pain at the injection site, tiredness, headache, redness and swelling at the site of injection, muscle pain and chills. These effects are usually mild or moderate and improve within a few days of vaccination.
The EMA concluded that the benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19.
The safety and efficacy of the vaccine in both children and adults will continue to be monitored closely as it is used in vaccination campaigns in EU member states as well as in ongoing and additional studies conducted by the company and by European authorities, it added.
Get a daily dose of Europe Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Europe Sun.
More InformationEVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
]LONDON, U.K.: A World Health Organization (WHO) expert group investigating the origins of the COVID-19 pandemic released its final...
DOVER, Delaware: California Governor Gavin Newsom has taken legal aim at Fox News, accusing the network of deliberately distorting...
FRANKFURT, Germany: Germany has become the latest country to challenge Chinese AI firm DeepSeek over its data practices, as pressure...
TORONTO, Canada: Harvard University and the University of Toronto have created a backup plan to ensure Harvard graduate students continue...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...